


Study design

Phase 3 giredestrant vs fulvestrant (+CDK4/6i) in 1L ETR ER+ HER2- aBC



¹pre/perimenopausal women and men should also receive LHRH agonist for the duration of study treatment in both arms

²valid results *ESR1*m vs. *ESR1*nmd (cap 60%) from central testing of baseline blood ctDNA by F1LCDx assay

³CDK4/6i of investigator's choice - palbociclib 125 mg QD D1–21 (cap 20%), ribociclib 600 mg QD D1–21, or abemaciclib 150 mg BID D1–28, of each 28-day cycle

⁴fulvestrant 500 mg IM administered on C1D1&D15, C2D1 and every 4 weeks thereafter

⁵secondary efficacy endpoints will be assessed in *ESR1*m and *ESR1*nmd subgroups and in FAS/ITT